Skip to content

Association of serum adropin with the presence and severity of type 2 diabetes in patients with obstructive sleep apnea syndrome

Association of serum adropin with the presence and severity of type 2 diabetes in patients with obstructive sleep apnea syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053655
Enrollment
Unknown
Registered
2021-11-26
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea

Interventions

healthy control group, OSA patients without type 2 diabetes and OSA patients with type 2 diabetes :Nil

Sponsors

University of Hong Kong-Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. According to the "American Academy of Sleep Medicine Clinical Practice Guidelines - Clinical Practice Guidelines for the Diagnosis of Obstructive Sleep Apnea", OSA was diagnosed based on the clinical manifestations of the subjects and the results of polysomnography, and the sleep apnea index (AHI) >= 5. 1530 is severe OSA; 2. Diabetes group: Diabetes symptoms (typical symptoms include polydipsia, polyuria, and unexplained weight loss) plus one of the following 3 are diagnostic: (1) Random blood sugar (referring to blood sugar at any time of day) >= 11.1 mmol/L (200mg%); (2) Fasting blood glucose (fasting state refers to no calorie intake for at least 8 hours) >= 7.0 mmol/L (126 mg%); (3) Blood glucose >= 11.1 mmol/L (200 mg%) 2 hours after glucose loading.

Exclusion criteria

Exclusion criteria: 1. Chronic obstructive pulmonary disease, upper respiratory tract infection, tumor, hypertension, cardiovascular disease, mental disease, autoimmune disease, kidney disease; 2. Frequent use of drugs that may interfere with glucose metabolism or the HPA axis, sedatives or narcotics, alcohol and drug abuse; 3. There is a history of OSA treatment before enrollment.

Design outcomes

Primary

MeasureTime frame
Adropin;

Secondary

MeasureTime frame
Tumor Necrosis Factor-a (TNF-a);Interleukin 6 (IL-6);High sensitive C-reactive protein (hsCRP);polysomnography;

Countries

China

Contacts

Public ContactJi Yang

University of Hong Kong-Shenzhen hospital

jiy@hku-szh.org+86 18928415076

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026